Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes
NCT ID: NCT03875469
Last Updated: 2021-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
425 participants
INTERVENTIONAL
2019-06-21
2020-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Compass Device CVC Trial
NCT03056859
Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route
NCT01531686
Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter
NCT02349308
REduction of Contrast Via DyeVert Used in CTO Procedures
NCT03118544
QStat Pilot Reference Range Study
NCT04490759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CT patients_Centargo_1
Adult patients referred for contrast-enhanced computed tomography in study part 1
Centargo injector (BPI 1000045)
Contrast-enhanced computer tomography conducted with Centargo injector
CT-patients_Stellant_1
Adult patients referred for contrast-enhanced computed tomography in study part 1
Stellant MP injector
Contrast-enhanced computer tomography conducted with Stellant MP injector
CT-patients_Centargo_2
Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)
Centargo injector (BPI 1000045)
Contrast-enhanced computer tomography conducted with Centargo injector
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Centargo injector (BPI 1000045)
Contrast-enhanced computer tomography conducted with Centargo injector
Stellant MP injector
Contrast-enhanced computer tomography conducted with Stellant MP injector
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with know hypersensitivity to iodinated contrast media
* Subjects with unacceptable renal function per local guidelines
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medscan
Merrylands, New South Wales, Australia
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find results for studies related to Bayer products
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20521
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.